Endurance Wealth Management Inc. Buys New Stake in Celgene Co. (CELG)

Endurance Wealth Management Inc. bought a new position in shares of Celgene Co. (NASDAQ:CELG) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,470 shares of the biopharmaceutical company’s stock, valued at approximately $943,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. BlackRock Inc. raised its position in shares of Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. State Street Corp raised its position in shares of Celgene by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Jennison Associates LLC raised its position in shares of Celgene by 1.2% in the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after buying an additional 156,864 shares during the last quarter. Finally, FMR LLC raised its position in shares of Celgene by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after buying an additional 697,250 shares during the last quarter. Institutional investors own 79.84% of the company’s stock.

Shares of Celgene Co. (NASDAQ:CELG) opened at $108.27 on Thursday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The stock has a market cap of $85,240.00, a P/E ratio of 16.88, a price-to-earnings-growth ratio of 0.84 and a beta of 1.77.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. Celgene’s revenue for the quarter was up 10.2% on a year-over-year basis. sell-side analysts predict that Celgene Co. will post 6.68 EPS for the current year.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.95% of the stock is owned by insiders.

A number of equities analysts have recently weighed in on the stock. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a research report on Monday. Cantor Fitzgerald reissued a “buy” rating and issued a $162.00 price objective on shares of Celgene in a research report on Tuesday, September 26th. Piper Jaffray Companies restated a “hold” rating on shares of Celgene in a report on Sunday, December 10th. BidaskClub upgraded shares of Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, Leerink Swann restated a “buy” rating and issued a $120.00 target price on shares of Celgene in a report on Wednesday, December 13th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Celgene presently has an average rating of “Buy” and a consensus price target of $136.21.

TRADEMARK VIOLATION NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/21/endurance-wealth-management-inc-buys-new-stake-in-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply